血小板与淋巴细胞比值对肝细胞癌患者预后影响的Meta分析
DOI: 10.3971/j.issn.1000-8578.2018.18.0151
Keywords: A Meta-analysis,Meta-analysis of Efficacy and Safety of Jinlong Capsule Combined with Chemoradiotherapy on Liver Metastases,Comparison of Efficacy Between S-1 and Capecitabine/Fluorouracil on Advanced Colorectal Cancer: A Meta-analysis,Influence of GSTP-1 Genetic Variation on Prognosis of Postoperative Glioblastoma Patients Received Temozolomide Combined with Radiotherapy Regimens,Clinicopathologic Characteristics and Prognosis of De Novo Metastatic Breast Cancer Patients,Prognostic and Clinicopathological Significance of PD-L1 Expression for Colorectal Cancer: A Meta-analysis,Value of 18F-FDG PET/CT in Evaluating Chemotherapeutic Effect of Diffuse Large B Cell Lymphoma Patients with Different CD5 Expression,Advances in Prognostic Value of Peripheral Blood Inflammatory Indexes in Non-small Cell Lung Cancer,Efficacy and Prognostic Factors of Docetaxel Rechallenge on Metastatic Castrationresistant Prostate Cancer Patients,Correlation Between Coke Oven Emissions and Death of Occupational Lung Cancer: A Meta-analysis,Cholesterol: A Predictor of Risk and Prognosis of Breast Cancer,Mechanism of D-bifunctional Protein Promoting Formation of Hepatocellular Carcinoma in Rat via STAT3,Predictive Value of Preoperative Hematologic Inflammatory Markers in Prognostic of Glioma Patients
Abstract:
摘要 目的 评价血小板与淋巴细胞比值（Platelet-lymphocyte ratio, PLR）对肝细胞癌（Hepatocellular carcinoma, HCC）的预后价值。方法 以PubMed、Embase、Web of Science数据库中已发表的英文文献作为检索的主要来源，检索时限为数据库建立至2016年12月31日，按照拟定的纳入和排除标准，筛选符合系统评价标准的研究。采用Meta分析方法评PLR对HCC的预后意义。数据分析软件采用STATA 12.0。异质性检验采用Cochran’s Q检验，根据检验结果选择模型进行相应的效应量合并，最终将合并分析所得出的HR/OR值及其95%CI作为效应分析的统计量。结果 来自6篇文献的1 215例HCC患者纳入研究。对于总体HCC人群而言，高水平PLR的HCC患者OS明显较短（HR=1.55, 95%CI: 1.06-2.29, P=0.025），但与DFS无相关性（P=0.222）。结论 PLR是影响HCC患者远期预后的独立风险因素。检测治疗前PLR水平对判断肝细胞癌患者的临床预后具有一定的意义
Full-Text
